Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Lockhart

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Lancet (London, England)|February 9, 2013
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialMichele D Tameris, Mark Hatherill, Bernard S Landry, et al.
Tuberculosis (Edinburgh, Scotland)|February 16, 2013
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCGMichele Tameris, Helen McShane, J Bruce McClain, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2014
An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solutionClaire S Waddington, Thomas C Darton, Claire Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile InfectionCurtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
Journal of the Pediatric Infectious Diseases Society|March 17, 2023
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year OldsEric A F Simões, Nicola P Klein, Charu Sabharwal, et al.
Plos Neglected Tropical Diseases|August 18, 2016
Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21aThomas C Darton, Claire Jones, Christoph J Blohmke, et al.
Nature|August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine|October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E Walsh, Robert Frenck, Ann R Falsey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2026
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years OldPatricia Winokur, Oyeniyi Diya, David Fitz-Patrick, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Lancet (London, England)|February 9, 2013
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialMichele D Tameris, Mark Hatherill, Bernard S Landry, et al.
Tuberculosis (Edinburgh, Scotland)|February 16, 2013
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCGMichele Tameris, Helen McShane, J Bruce McClain, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2014
An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solutionClaire S Waddington, Thomas C Darton, Claire Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2024
CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile InfectionCurtis J Donskey, Erik R Dubberke, Nicola P Klein, et al.
Journal of the Pediatric Infectious Diseases Society|March 17, 2023
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year OldsEric A F Simões, Nicola P Klein, Charu Sabharwal, et al.
Plos Neglected Tropical Diseases|August 18, 2016
Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21aThomas C Darton, Claire Jones, Christoph J Blohmke, et al.
Nature|August 14, 2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J Mulligan, Kirsten E Lyke, Nicholas Kitchin, et al.
The New England Journal of Medicine|October 14, 2020
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E Walsh, Robert W Frenck, Ann R Falsey, et al.
Medrxiv : the Preprint Server for Health Sciences|August 26, 2020
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E Walsh, Robert Frenck, Ann R Falsey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2026
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years OldPatricia Winokur, Oyeniyi Diya, David Fitz-Patrick, et al.
Pageof 4